GAL 021

Drug Profile

GAL 021

Alternative Names: GAL021

Latest Information Update: 10 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galleon Pharmaceuticals
  • Class Nitroso compounds; Small molecules
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Respiratory insufficiency

Most Recent Events

  • 10 May 2016 Phase I development is ongoing in USA
  • 13 Oct 2014 Phase-I development is ongoing in USA
  • 16 Apr 2013 Clinical proof-of-concept and adverse events data from a phase I trial in Respiratory insufficiency released by Galleon Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top